Supplemental Table 1. Correlations among inflammation and coagulation biomarkers.

		HIV-infected women, prior to HAART initiaiton						
		IL-10	TNF-a	D-dimer	MCP-1	sCD14	Fibrinogen	IL-2 sR
IL-6	r	0.18	0.24	0.20	0.21	0.33	0.10	0.30
	P	0.047	0.010	0.025	0.022	<.0001	0.301	0.001
IL-10	r		0.57	0.14	0.32	0.45	0.08	0.42
	P		<.0001	0.120	<.0001	<.0001	0.402	<.0001
TNF-a	r			0.32	0.45	0.43	0.12	0.52
	P			0.000	<.0001	<.0001	0.176	<.0001
D-dimer	r				0.17	0.28	0.28	0.20
	P				0.058	0.001	0.001	0.025
MCP-1	r					0.34	0.11	0.45
	P					<.0001	0.224	<.0001
sCD14	r						0.16	0.56
	P						0.070	<.0001
Fibrinogen	r							0.05
	P							0.561

		HIV-infected women, after HAART initiaiton						
		IL-10	TNF-a	D-dimer	MCP-1	sCD14	Fibrinogen	IL-2 sR
IL-6	r	0.19	0.21	0.17	0.22	0.27	0.24	0.38
	P	0.037	0.019	0.061	0.017	0.003	0.010	<.0001
IL-10	r		0.70	0.46	0.36	0.26	0.11	0.38
	P		<.0001	<.0001	<.0001	0.003	0.226	<.0001
TNF-a	r			0.61	0.58	0.25	0.20	0.40
	P			<.0001	<.0001	0.005	0.022	<.0001
D-dimer	r				0.30	0.12	0.34	0.19
	P				0.001	0.191	<.0001	0.031
MCP-1	r					0.22	0.19	0.37
	P					0.012	0.032	<.0001
sCD14	r						0.03	0.38
	P						0.714	<.0001
Fibrinogen	r							0.10
	P							0.257

		HIV-uninfected women						
		IL-10	TNF-a	D-dimer	MCP-1	sCD14	Fibrinogen	IL-2 sR
IL-6	r	0.16	0.23	0.23	-0.17	0.27	0.02	0.19
	P	0.145	0.030	0.029	0.121	0.011	0.867	0.079
IL-10	r		0.65	0.18	0.18	0.28	-0.08	0.33
	P		<.0001	0.095	0.085	0.007	0.426	0.001
TNF-a	r			0.45	0.35	0.33	0.04	0.46
	P			<.0001	0.001	0.002	0.726	<.0001
D-dimer	r				0.03	0.13	0.12	0.09
	P				0.784	0.209	0.245	0.390
MCP-1	r					0.17	0.11	0.25
	P					0.111	0.279	0.019
sCD14	r						0.06	0.37
	P						0.557	<.0001
Fibrinogen	r							-0.01
	P							0.910

Correlations represent Pearson correlations of natural log-transformed biomarker levels

Supplemental Table 2. Correlations of inflammation and coagulation biomarkers with current and nadir CD4+ T cell count, HIV RNA and clinical characteristics among HIV-infected women

	Age		Current CD4+ T Cell Count		Nadir CD4+ T Cell Count		HIV RNA		Smoking History (in years)		BMI		HCV Ab/RNA Status	
	r	*P*	*r*	*P*	*r*	*P*	*r*	*P*	*r*	*P*	*r*	*P*	*r*	*P*
Prior to HAART initiation:														
sCD14	0.18	0.04	-0.25	0.01	-0.29	<0.01	0.41	<.0001	0.15	0.09	-0.11	0.20	0.27	<0.01
TNF-alpha	0.04	0.65	-0.19	0.03	-0.22	0.01	0.24	0.01	-0.04	0.64	0.02	0.87	0.14	0.13
IL-2 sR	0.02	0.78	-0.15	0.10	-0.28	<0.01	0.42	<.0001	0.13	0.16	-0.02	0.83	0.16	0.08
IL-6	0.19	0.04	-0.18	0.05	-0.24	0.01	0.13	0.16	0.34	<0.01	0.05	0.60	0.34	<0.01
IL-10	-0.05	0.60	-0.22	0.01	-0.29	<0.01	0.33	0.00	0.03	0.74	-0.07	0.42	0.18	0.04
MCP-1	0.08	0.38	-0.14	0.12	-0.21	0.02	0.28	<0.01	-0.14	0.13	-0.02	0.82	0.01	0.88
D-dimer	-0.02	0.79	-0.09	0.30	-0.14	0.11	0.18	0.04	-0.04	0.63	0.01	0.92	-0.05	0.57
Fibrinogen	0.18	0.05	0.03	0.72	-0.02	0.85	0.15	0.09	0.02	0.79	0.16	0.07	-0.07	0.43
After HAART initiation														
sCD14	0.10	0.25	-0.23	0.01	-0.23	0.01	0.14	0.13	0.00	0.99	-0.06	0.53	0.13	0.16
TNF-alpha	0.06	0.50	-0.24	0.01	-0.29	<0.01	0.28	<0.01	0.08	0.37	0.06	0.53	0.20	0.03
IL-2 sR	0.04	0.66	-0.14	0.12	-0.26	<0.01	0.31	<0.01	0.15	0.08	0.15	0.10	0.22	0.01
IL-6	0.30	<0.01	-0.18	0.05	-0.27	<0.01	0.12	0.21	0.34	<0.01	0.08	0.38	0.31	<0.01
IL-10	-0.03	0.75	-0.21	0.02	-0.29	<0.01	0.28	<0.01	0.15	0.09	-0.01	0.95	0.31	<0.01
MCP-1	0.07	0.42	-0.08	0.39	-0.09	0.29	0.19	0.03	-0.14	0.13	0.14	0.13	0.12	0.20
D-dimer	-0.08	0.40	-0.11	0.22	-0.10	0.28	0.22	0.01	-0.05	0.58	0.08	0.36	0.03	0.75
Fibrinogen	0.23	0.01	0.01	0.92	0.01	0.93	0.12	0.19	0.09	0.30	0.19	0.04	-0.12	0.20

r represents Pearson correlation coefficient

Biomarkers are natural log-transformed and HIV RNA is log10-transformed

Supplemental Table 3. Correlation between HAART-associated change in CD4+ T cell count or HIV RNA and concomitant change in inflammation or hemostasis biomarkers

	Biomarker change per 100 cell/mm^3 increase in CD4+ T cell count	*P*	Biomarker change per log_{10} decrease in HIV RNA	*P*
Soluble CD14	-2%	<.01	-2%	0.05
TNF-alpha	-8%	<.0001	-11%	<.0001
Soluble IL-2 receptor	-8%	<.0001	-13%	<.0001
IL-6	-5%	0.14	-2%	0.63
IL-10	-10%	<.0001	-15%	<.0001
MCP-1	-5%	<.01	-6%	<.01
D-dimer	-3%	0.3	-3%	0.52
Fibrinogen	0	0.9	0	0.76

HAART, highly active antiretroviral therapy

Supplemental Table 4. Correlation of hepatitis C virus infection (HCV RNA+) with levels of circulating inflammation and coagulation biomarkers

	HIV-infected women				HIV-uninfected women	
	Prior to HAART		After HAART initiation			
	r	*P*	*r*	*P*	*r*	*P*
sCD14	0.27	<0.01	0.13	0.16	0.45	<0.01
TNF-alpha	0.14	0.13	0.20	0.03	0.32	<0.01
IL-2sr	0.16	0.08	0.22	0.01	0.29	0.01
IL-6	0.34	<0.01	0.31	<0.01	0.25	0.02
IL-10	0.18	0.04	0.31	<0.01	0.45	<0.01
MCP-1	0.01	0.88	0.12	0.20	-0.02	0.84
D-dimer	-0.05	0.57	0.03	0.75	0.09	0.41
Fibrinogen	-0.07	0.43	-0.12	0.20	-0.25	0.02

r represents Pearson correlation between presence or absence of hepatitis C virus infection (HCV RNA+) and natural log-transformed level of biomarker

HAART, highly-active antiretroviral therapy

Supplemental Table 5. Levels of soluble CD14 (ng/mL) among HIV-infected women before and after initiation of highly-active antiretroviral therapy, and among HIV-uninfected women, in the presence or absence of hepatitis C infection

	HCV-infected women					HCV-uninfected women				
	HIV-infected (N=27)		HIV-uninfected (N=32)			HIV-infected (N=100)		HIV-uninfected (N=95)		
	Median sCD14, ng/mL	IQR	Median sCD14, ng/mL	IQR	*P*	Median sCD14, ng/mL	IQR	Median sCD14, ng/mL	IQR	*P*
1st visit	2246	1623-2657	1872	1640-2169	0.07	1888	1612-2093	1509	1331-1781	<0.0001
2nd visit	2326	2120-2598	1923	1618-2125	0.001	1866	1636-2120	1564	1333-1824	<0.0001
3rd visit	2265	2048-2578	1966	1724-2293	0.02	1915	1586-2220	1566	1344-1877	<0.0001
4th visit	2115	1786-2461	2010	1729-2207	0.10	1891	1585-2142	1614	1371-1916	0.0002
5th visit	1978	1604-2412	1990	1719-2268	0.82	1919	1655-2273	1566	1358-1834	<0.0001
6th visit	2126	1713-2420	2057	1735-2420	0.44	1956	1639-2180	1594	1414-1911	<0.0001

P values calculated using the Mann-Whitney test. HCV infection status was defined as presence or absence of circulating HCV RNA.

HCV, hepatitis C virus; IQR, interquartile range

Supplemental Figure 1. Levels of soluble CD14 (ng/mL) among HIV-infected women before and after initiation of highly-active antiretroviral therapy, and among HIV-uninfected women, in the presence or absence of hepatitis C infection



Blue diamonds indicate median values among HIV-infected women at six semi-annual study visits. Red x's indicate median values among HIV-uninfected women. Green arrow indicates time of HAART initiation. HCV infection status was defined as presence or absence of circulating HCV RNA.

HCV, hepatitis C virus; HAART, highly-active antiretroviral therapy